337 related articles for article (PubMed ID: 32869445)
21. The slow-release adiponectin analog ALY688-SR modifies early-stage disease development in the D2.
Bellissimo CA; Gandhi S; Castellani LN; Murugathasan M; Delfinis LJ; Thuhan A; Garibotti MC; Seo Y; Rebalka IA; Hsu HH; Sweeney G; Hawke TJ; Abdul-Sater AA; Perry CGR
Am J Physiol Cell Physiol; 2024 Apr; 326(4):C1011-C1026. PubMed ID: 38145301
[TBL] [Abstract][Full Text] [Related]
22. A new therapeutic effect of fenofibrate in Duchenne muscular dystrophy: The promotion of myostatin degradation.
Sun Z; Xu D; Zhao L; Li X; Li S; Huang X; Li C; Sun L; Liu B; Jiang Z; Zhang L
Br J Pharmacol; 2022 Mar; 179(6):1237-1250. PubMed ID: 34553378
[TBL] [Abstract][Full Text] [Related]
23. Assessing the Use of the sGC Stimulator BAY-747, as a Potential Treatment for Duchenne Muscular Dystrophy.
Krishnan SM; Nordlohne J; Dietz L; Vakalopoulos A; Haning P; Hartmann E; Seifert R; Hüser J; Mathar I; Sandner P
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360780
[TBL] [Abstract][Full Text] [Related]
24. Improvement of Duchenne muscular dystrophy phenotype following obestatin treatment.
González-Sánchez J; Sánchez-Temprano A; Cid-Díaz T; Pabst-Fernández R; Mosteiro CS; Gallego R; Nogueiras R; Casabiell X; Butler-Browne GS; Mouly V; Relova JL; Pazos Y; Camiña JP
J Cachexia Sarcopenia Muscle; 2018 Dec; 9(6):1063-1078. PubMed ID: 30216693
[TBL] [Abstract][Full Text] [Related]
25. miR-146a deficiency does not aggravate muscular dystrophy in mdx mice.
Bronisz-Budzyńska I; Chwalenia K; Mucha O; Podkalicka P; Karolina-Bukowska-Strakova ; Józkowicz A; Łoboda A; Kozakowska M; Dulak J
Skelet Muscle; 2019 Aug; 9(1):22. PubMed ID: 31412923
[TBL] [Abstract][Full Text] [Related]
26. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys.
St Andre M; Johnson M; Bansal PN; Wellen J; Robertson A; Opsahl A; Burch PM; Bialek P; Morris C; Owens J
Skelet Muscle; 2017 Nov; 7(1):25. PubMed ID: 29121992
[TBL] [Abstract][Full Text] [Related]
27. Loss of full-length dystrophin expression results in major cell-autonomous abnormalities in proliferating myoblasts.
Gosselin MRF; Mournetas V; Borczyk M; Verma S; Occhipinti A; Róg J; Bozycki L; Korostynski M; Robson SC; Angione C; Pinset C; Gorecki DC
Elife; 2022 Sep; 11():. PubMed ID: 36164827
[TBL] [Abstract][Full Text] [Related]
28. Targeted regulation of TAK1 counteracts dystrophinopathy in a DMD mouse model.
Roy A; Koike TE; Joshi AS; Tomaz da Silva M; Mathukumalli K; Wu M; Kumar A
JCI Insight; 2023 May; 8(10):. PubMed ID: 37071470
[TBL] [Abstract][Full Text] [Related]
29. Cardiac Protection after Systemic Transplant of Dystrophin Expressing Chimeric (DEC) Cells to the mdx Mouse Model of Duchenne Muscular Dystrophy.
Siemionow M; Malik M; Langa P; Cwykiel J; Brodowska S; Heydemann A
Stem Cell Rev Rep; 2019 Dec; 15(6):827-841. PubMed ID: 31612351
[TBL] [Abstract][Full Text] [Related]
30. Validation of ultrasonography for non-invasive assessment of diaphragm function in muscular dystrophy.
Whitehead NP; Bible KL; Kim MJ; Odom GL; Adams ME; Froehner SC
J Physiol; 2016 Dec; 594(24):7215-7227. PubMed ID: 27570057
[TBL] [Abstract][Full Text] [Related]
31. Neopterin/7,8-dihydroneopterin is elevated in Duchenne muscular dystrophy patients and protects mdx skeletal muscle function.
Lindsay A; Schmiechen A; Chamberlain CM; Ervasti JM; Lowe DA
Exp Physiol; 2018 Jul; 103(7):995-1009. PubMed ID: 29791760
[TBL] [Abstract][Full Text] [Related]
32. Cytoplasmic HDAC4 regulates the membrane repair mechanism in Duchenne muscular dystrophy.
Renzini A; Marroncelli N; Cavioli G; Di Francescantonio S; Forcina L; Lambridis A; Di Giorgio E; Valente S; Mai A; Brancolini C; Giampietri C; Magenta A; De Santa F; Adamo S; Coletti D; Moresi V
J Cachexia Sarcopenia Muscle; 2022 Apr; 13(2):1339-1359. PubMed ID: 35170869
[TBL] [Abstract][Full Text] [Related]
33. Placenta-derived mesenchymal stromal cells and their exosomes exert therapeutic effects in Duchenne muscular dystrophy.
Bier A; Berenstein P; Kronfeld N; Morgoulis D; Ziv-Av A; Goldstein H; Kazimirsky G; Cazacu S; Meir R; Popovtzer R; Dori A; Brodie C
Biomaterials; 2018 Aug; 174():67-78. PubMed ID: 29783118
[TBL] [Abstract][Full Text] [Related]
34. Nutraceutical and pharmaceutical cocktails did not improve muscle function or reduce histological damage in D2-mdx mice.
Spaulding HR; Quindry T; Hammer K; Quindry JC; Selsby JT
J Appl Physiol (1985); 2019 Oct; 127(4):1058-1066. PubMed ID: 31295065
[TBL] [Abstract][Full Text] [Related]
35. Long-term effect of human mini-dystrophin in transgenic mdx mice improves muscle physiological function.
Chu X; Li J; Qiao C; Wang J; Wang Y; Jiang XC; You H; Xiao X; Wang B
FASEB J; 2021 Jun; 35(6):e21628. PubMed ID: 33982338
[TBL] [Abstract][Full Text] [Related]
36. SU9516 Increases α7β1 Integrin and Ameliorates Disease Progression in the mdx Mouse Model of Duchenne Muscular Dystrophy.
Sarathy A; Wuebbles RD; Fontelonga TM; Tarchione AR; Mathews Griner LA; Heredia DJ; Nunes AM; Duan S; Brewer PD; Van Ry T; Hennig GW; Gould TW; Dulcey AE; Wang A; Xu X; Chen CZ; Hu X; Zheng W; Southall N; Ferrer M; Marugan J; Burkin DJ
Mol Ther; 2017 Jun; 25(6):1395-1407. PubMed ID: 28391962
[TBL] [Abstract][Full Text] [Related]
37. Iron overload and impaired iron handling contribute to the dystrophic pathology in models of Duchenne muscular dystrophy.
Alves FM; Kysenius K; Caldow MK; Hardee JP; Chung JD; Trieu J; Hare DJ; Crouch PJ; Ayton S; Bush AI; Lynch GS; Koopman R
J Cachexia Sarcopenia Muscle; 2022 Jun; 13(3):1541-1553. PubMed ID: 35249268
[TBL] [Abstract][Full Text] [Related]
38. Muscle-specific deletion of SLK/Stk2 enhances p38 activity and myogenesis in mdx mice.
Pryce BR; Labrèche C; Hamoudi D; Abou-Hamad J; Al-Zahrani KN; Hodgins JJ; Boulanger-Piette A; Bossé S; Balog-Alvarez C; Frénette J; Ardolino M; Kornegay JN; Sabourin LA
Biochim Biophys Acta Mol Cell Res; 2021 Feb; 1868(2):118917. PubMed ID: 33259860
[TBL] [Abstract][Full Text] [Related]
39. Intermittent PTH treatment improves bone and muscle in glucocorticoid treated Mdx mice: A model of Duchenne Muscular Dystrophy.
Yoon SH; Grynpas M; Mitchell J
Bone; 2019 Apr; 121():232-242. PubMed ID: 30716510
[TBL] [Abstract][Full Text] [Related]
40. Increased plasma lipid levels exacerbate muscle pathology in the mdx mouse model of Duchenne muscular dystrophy.
Milad N; White Z; Tehrani AY; Sellers S; Rossi FMV; Bernatchez P
Skelet Muscle; 2017 Sep; 7(1):19. PubMed ID: 28899419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
